{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T23:33:32Z","timestamp":1792020812034,"version":"4.4.0"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2013,6,19]],"date-time":"2013-06-19T00:00:00Z","timestamp":1371600000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur Arch Otorhinolaryngol"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1007\/s00405-013-2596-8","type":"journal-article","created":{"date-parts":[[2013,6,18]],"date-time":"2013-06-18T09:17:34Z","timestamp":1371547054000},"page":"887-897","source":"Crossref","is-referenced-by-count":64,"title":["Meta-analysis of clinical studies with betahistine in M\u00e9ni\u00e8re\u2019s disease and vestibular vertigo"],"prefix":"10.1007","volume":"271","author":[{"given":"Jozef J. P.","family":"Nauta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,6,19]]},"reference":[{"key":"2596_CR1","doi-asserted-by":"crossref","unstructured":"(1995) American Academy of Otolaryngology-Head and Neck Foundation. Committee on Hearing and Equilibrium guidelines for the diagnosis and evaluation of therapy in M\u00e9ni\u00e8re\u2019s disease. Otolaryngol Head Neck Surg. 113:181\u2013185","DOI":"10.1016\/S0194-5998(95)70102-8"},{"key":"2596_CR2","first-page":"20","volume":"9","author":"TL Thompson","year":"2009","unstructured":"Thompson TL, Amedee R (2009) A review of common peripheral and central vestibular disorders. Ochsner J. 9:20\u201326","journal-title":"Ochsner J."},{"key":"2596_CR3","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2165\/00023210-200317020-00002","volume":"17","author":"TC Hain","year":"2003","unstructured":"Hain TC, Uddin M (2003) Pharmacological treatment of vertigo. CNS Drugs 17:85\u2013100","journal-title":"CNS Drugs"},{"key":"2596_CR4","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/S0140-6736(08)61161-7","volume":"372","author":"H Sajjadi","year":"2008","unstructured":"Sajjadi H, Paparella MM (2008) M\u00e9ni\u00e8re\u2019s disease. Lancet 372:406\u2013414","journal-title":"Lancet"},{"key":"2596_CR5","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s00415-006-0340-7","volume":"254","author":"M Dieterich","year":"2007","unstructured":"Dieterich M (2007) Central vestibular disorders. J Neurol 254:559\u2013568","journal-title":"J Neurol"},{"key":"2596_CR6","first-page":"429","volume":"3","author":"M Lacour","year":"2007","unstructured":"Lacour M, van de Heyning PH, Novotny M, Tighilet B (2007) Betahistine in the treatment of M\u00e9ni\u00e8re\u2019s disease. Neuropsychiatr Dis Treat 3:429\u2013440","journal-title":"Neuropsychiatr Dis Treat"},{"key":"2596_CR7","doi-asserted-by":"crossref","first-page":"228","DOI":"10.3109\/00016489.2010.531052","volume":"131","author":"D Huppert","year":"2011","unstructured":"Huppert D, Strupp M, M\u00fcckter H, Brandt T (2011) Which medication do I need to manage dizzy patients? Acta Otolaryngol 131:228\u2013241","journal-title":"Acta Otolaryngol"},{"key":"2596_CR8","doi-asserted-by":"crossref","first-page":"e39086","DOI":"10.1371\/journal.pone.0039086","volume":"7","author":"F Ihler","year":"2012","unstructured":"Ihler F, Bertlich M, Sharaf K, Strieth S, Strupp M, Canis M (2012) Betahistine exerts a dose-dependent effect on cochlear stria vascularis blood flow in Guinea Pigs in vivo. PLoS ONE 7:e39086","journal-title":"PLoS ONE"},{"key":"2596_CR9","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1288\/00005537-196911000-00008","volume":"79","author":"F Suga","year":"1969","unstructured":"Suga F, Snow JB Jr (1969) Cochlear blood flow in response to vasodilating drugs and some related agents. Laryngoscope 79:1956\u20131979","journal-title":"Laryngoscope"},{"key":"2596_CR10","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s004050050025","volume":"255","author":"E Laurikainen","year":"1998","unstructured":"Laurikainen E, Miller JM, Nuttall AL, Quirk WS (1998) The vascular mechanism of action of betahistine in the inner ear of the guinea pig. Eur Arch Otorhinolaryngol 255:119\u2013123","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"2596_CR11","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1002\/j.1552-4604.1974.tb02314.x","volume":"14","author":"JS Meyer","year":"1974","unstructured":"Meyer JS, Mathew NT, Hartmann A, Rivera VM (1974) Orally administered betahistine and regional cerebral blood flow in cerebrovascular disease. J Clin Pharmacol 14:280\u2013289","journal-title":"J Clin Pharmacol"},{"key":"2596_CR12","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1161\/01.STR.9.4.382","volume":"9","author":"M Tomita","year":"1978","unstructured":"Tomita M, Gotoh F, Sato T, Amano T, Tanahashi N, Tanaka K, Yamamoto M (1978) Comparative responses of the carotid and vertebral arterial systems of rhesus monkeys to betahistine. Stroke 9:382\u2013387","journal-title":"Stroke"},{"key":"2596_CR13","first-page":"255","volume":"48","author":"BA Krishna","year":"2000","unstructured":"Krishna BA, Kirtane MV, Sangeeta T, Gopinath G (2000) Pre and post betahistine therapy 99mTc-HMPAO brain spect studies in patients with vertigo. Neurol India 48:255\u2013259","journal-title":"Neurol India"},{"key":"2596_CR14","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/BF00454214","volume":"236","author":"H Unemoto","year":"1982","unstructured":"Unemoto H, Sasa M, Takaori S, Ito J, Matsuoka I (1982) Effects et al. Inhibitory effect of betahistine on polysynaptic neurons in the lateral vestibular nucleus. Arch Otorhinolaryngol 236:229\u2013236","journal-title":"Arch Otorhinolaryngol"},{"key":"2596_CR15","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1080\/000164800750044416","volume":"544","author":"P Valli","year":"2000","unstructured":"Valli P (2000) Betahistine reduces the resting firing rate of vestibular receptors in the frog. Acta Otolaryngol Suppl 544:8\u201310","journal-title":"Acta Otolaryngol Suppl"},{"key":"2596_CR16","first-page":"19","volume":"545","author":"E Soto","year":"2001","unstructured":"Soto E, Ch\u00e1vez H, Valli P, Benvenuti C, Vega R (2001) Betahistine produces post-synaptic inhibition of the excitability of the primary afferent neurons in the vestibular end organs. Acta Otolaryngol Suppl 545:19\u201324","journal-title":"Acta Otolaryngol Suppl"},{"key":"2596_CR17","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1080\/00016489850154658","volume":"118","author":"L Botta","year":"1998","unstructured":"Botta L, Mira E, Valli S, Zucca G, Valli P (1998) Effects of betahistine on vestibular receptors of the frog. Acta Otolaryngol 118:519\u2013523","journal-title":"Acta Otolaryngol"},{"key":"2596_CR18","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1080\/000164800760370783","volume":"120","author":"L Botta","year":"2000","unstructured":"Botta L, Mira E, Valli S, Zucca G, Perin P, Benvenuti C, Fossati A, Valli P (2000) Effects of betahistine metabolites on frog ampullar receptors. Acta Otolaryngol 120:25\u201327","journal-title":"Acta Otolaryngol"},{"key":"2596_CR19","unstructured":"James A, Burton MJ (2011) Betahistine for M\u00e9ni\u00e8re\u2019s disease or syndrome (review). The Cochrane Library"},{"key":"2596_CR20","first-page":"208","volume":"26","author":"C Della Pepa","year":"2003","unstructured":"Della Pepa C, Guidetti G, Eandi M (2003) Betahistine in the treatment of vertiginous syndromes: a meta-analysis. Acta Otorhinolaryngol Ital 26:208\u2013215","journal-title":"Acta Otorhinolaryngol Ital"},{"key":"2596_CR21","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1002\/sim.4780132313","volume":"13","author":"A Whitehead","year":"1994","unstructured":"Whitehead A, Jones N (1994) A meta-analysis of clinical trials involving different classifications of response into ordered categories. Stat Med 13:2503\u20132515","journal-title":"Stat Med"},{"key":"2596_CR22","volume-title":"Methods for meta-analysis in medical research","author":"AJ Sutton","year":"2000","unstructured":"Sutton AJ, Abrams KR, Jones DR, Sheldon TA, Song F (2000) Methods for meta-analysis in medical research. Wiley, Chichester"},{"key":"2596_CR23","unstructured":"ICH E9 (1998) Statistical principles of clinical trials. (CPMP\/ICH\/363\/96)"},{"key":"2596_CR24","volume-title":"Applied mixed models in medicine","author":"H Brown","year":"1999","unstructured":"Brown H, Prescott R (1999) Applied mixed models in medicine. Wiley, New York"},{"key":"2596_CR25","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177\u2013188","journal-title":"Control Clin Trials"},{"key":"2596_CR26","first-page":"1237","volume":"39","author":"K Watanabe","year":"1967","unstructured":"Watanabe K, Fukami J, Yoshimoto H, Ueda M, Suzuki J (1967) Evaluation of the effect of betahistine in M\u00e9ni\u00e8re\u2019s disease by double-blind test and multivariate analysis. Jibiinkoka 39:1237\u20131250","journal-title":"Jibiinkoka"},{"key":"2596_CR27","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1136\/pgmj.52.610.501","volume":"52","author":"IJC Frew","year":"1976","unstructured":"Frew IJC, Menon GN (1976) Betahistine hydrochloride in M\u00e9ni\u00e8re\u2019s disease. Postgrad Med J 52:501\u2013503","journal-title":"Postgrad Med J"},{"key":"2596_CR28","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1017\/S0022215100082785","volume":"90","author":"TJ Wilmot","year":"1976","unstructured":"Wilmot TJ, Menon GN (1976) Betahistine in M\u00e9ni\u00e8re\u2019s disease. J Laryngol Otol 90:833\u2013840","journal-title":"J Laryngol Otol"},{"key":"2596_CR29","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1017\/S0022215100146158","volume":"98","author":"WJ Oosterveld","year":"1984","unstructured":"Oosterveld WJ (1984) Betahistine dihydrochloride in the treatment of vertigo of peripheral vestibular origin: a double-blind placebo controlled study. J Laryngol Otol 98:37\u201341","journal-title":"J Laryngol Otol"},{"key":"2596_CR30","unstructured":"Mak M (1981) Betahistine dihydrochloride and vertigo of the peripheral type: a double-blind cross-over clinical trial in out-patients. Duphar report 56638\/9M\/81"},{"key":"2596_CR31","unstructured":"Mak M (1982) Double-blind cross-over multi-centre trial of SERC (betahistine hydrochloride) 48\u00a0mg daily versus placebo in outpatients with vertigo. Duphar report 56638\/1M\/82"},{"key":"2596_CR32","unstructured":"Kastein ETh (1983) A double blind cross-over study of Serc (betahistine dihydrochloride), 36\u00a0mg daily, versus placebo in outpatients with vertigo. Duphar report H108.5009"},{"key":"2596_CR33","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1055\/s-2007-1008135","volume":"64","author":"ED Meyer","year":"1985","unstructured":"Meyer ED (1985) Treatment of M\u00e9ni\u00e8re\u2019s disease with betahistine dimesilate (Aequamen\u00ae)\u2014double blind study versus placebo (cross-over). Laryngol Rhinol Otol 64:269\u2013272","journal-title":"Laryngol Rhinol Otol"},{"key":"2596_CR34","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1001\/archotol.1967.00760050612003","volume":"86","author":"JJ Hicks","year":"1967","unstructured":"Hicks JJ, Hicks JN, Cooley HN (1967) M\u00e9ni\u00e8re\u2019s disease. Arch Otolaryngol 86:610\u2013613","journal-title":"Arch Otolaryngol"},{"key":"2596_CR35","first-page":"891","volume":"46","author":"RJ Wolfson","year":"1967","unstructured":"Wolfson RJ, Myeres D, Schlosser WD (1967) M\u00e9ni\u00e8re\u2019s disease\u2014treatment with betahistine hydrochloride. Eye Ear Nose Throat Mon 46:891\u2013896","journal-title":"Eye Ear Nose Throat Mon"},{"key":"2596_CR36","first-page":"47","volume":"30","author":"J Martins","year":"1968","unstructured":"Martins J (1968) New basis for control of M\u00e9ni\u00e8re\u2019s disease. Eye Ear Nose Throat Digest 30:47\u201351","journal-title":"Eye Ear Nose Throat Digest"},{"key":"2596_CR37","unstructured":"Singarelli S (1979) Studio in doppio cieco sull\u2019efficacia del cloroidrato di betaistina nel trattamento ambulatoriale di un gruppo di pazienti affetti da vertigine di posizione e acufeni [Double blind study into the efficacy of betahistine hydrochloride in the outpatient treatment of a group of patients affected by positional vertigo and tinnitus.] Nuovo Arch Ital Otol Suppl 7:69\u201372"},{"key":"2596_CR38","first-page":"650","volume":"22","author":"K Okamato","year":"1968","unstructured":"Okamato K, Hazeyama F, Taira T, Yoshida A (1968) Therapeutic results of betahistine in M\u00e9ni\u00e8re\u2019s disease with statistical analysis. Iryo 22:650\u2013666","journal-title":"Iryo"},{"key":"2596_CR39","unstructured":"Salami A, Delle Piane M, Tinelli E, Jankowska B (1984) Studio a doppia cecita\u2019 tra cloridrato di betaistina e placebo nel traptament o deele sindromi Menieriformi [Double-blind study of betahistine hydrochloride and placebo in the treatment of forms of Meniere\u2019s syndrome]. I1 Valsalva 60:302\u2013312"},{"key":"2596_CR40","first-page":"1","volume":"497","author":"JT Schmidt","year":"1992","unstructured":"Schmidt JT, Huizing EH (1992) The clinical drug trial in M\u00e9ni\u00e8re\u2019s disease with emphasis on the effect of betahistine SR. Acta Otolaryngol Suppl 497:1\u2013189","journal-title":"Acta Otolaryngol Suppl"},{"key":"2596_CR41","unstructured":"Le Gourrierec (2010) A double-blind, placebo-controlled, randomized, clinical study of the effects of Betaserc\u00ae 24\u00a0mg (1 tablet b.i.d. over 3\u00a0months) on vestibular compensation following vestibular neurotomy in patients with disabling M\u00e9ni\u00e8re\u2019s disease. Solvay Pharmaceuticals report S108.4.102"},{"key":"2596_CR42","first-page":"187","volume":"196","author":"JC Elia","year":"1966","unstructured":"Elia JC (1966) Double-blind evaluation of a new treatment for M\u00e9ni\u00e8re\u2019s syndrome. JAMA 196:187\u2013189","journal-title":"JAMA"},{"key":"2596_CR43","first-page":"41","volume":"74","author":"A Burkin","year":"1967","unstructured":"Burkin A (1967) Betahistine treatment of M\u00e9ni\u00e8re\u2019s syndrome. Clin Med 74:41\u201348","journal-title":"Clin Med"},{"key":"2596_CR44","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1017\/S0022215100091283","volume":"95","author":"P Canty","year":"1981","unstructured":"Canty P, Valentine J, Papworth SJ (1981) Betahistine in peripheral vertigo: a double-blind, placebo controlled cross-over study of Serc versus placebo. J Laryngol Otol 95:687\u2013692","journal-title":"J Laryngol Otol"},{"key":"2596_CR45","unstructured":"Van Bemmel P (1978) Statistical analysis of the data of a double blind cross-over study of Serc and placebo in outpatients with vertigo of the peripheral type. Philips Duphar report 56663\/26\/78"},{"key":"2596_CR46","unstructured":"Kastein ETh (1983) Betahistine dihydrochloride and peripheral vertigo, a double blind placebo-controlled trial in outpatients. Duphar report 77.054"},{"key":"2596_CR47","unstructured":"Nury AM (1984) A prospectively randomized, placebo-controlled, double-blind, parallel group study of betahistine dihydrochloride in patients presenting with vertigo and central signs on electronystagmography. Duphar report 108.005 80\/M"},{"key":"2596_CR48","unstructured":"Fischer AJEM, van Elferen LWM (1985) Betahistine bij de behandeling van aanvalsgewijs optredende duizeligheid. Een dubbelblind onderzoek. [Betahistine in the treatment of paroxysmal attacks of vertigo. A double-blind investigation]. Tijdschr Ther Geneesm Onderz 10:933\u2013937"},{"key":"2596_CR49","unstructured":"Van Delden RAJ (1984) A multicentre randomised double-blind placebo controlled general practitioner study with betahistine (Betaserc\u00ae) in the treatment of paroxysmal vertigo. Duphar report H 108.903 NL"},{"key":"2596_CR50","first-page":"347","volume":"7","author":"V Ricci","year":"1987","unstructured":"Ricci V, Sittoni V, Nicora M (1987) Valutazione terapeutica e tollerabilita del chloridrato di betaistina (Microser) in confronto a placebo nella malattia diMeni\u00e8re [Efficacy and safety of betahistine hydrochloride versus placebo in M\u00e9ni\u00e8re\u2019s disease]. Riv Ital Ornitol Audiol Foniatr 7:347\u2013350","journal-title":"Riv Ital Ornitol Audiol Foniatr"},{"key":"2596_CR51","first-page":"2539","volume":"110","author":"F Legent","year":"1988","unstructured":"Legent F, Calais C, Celleir D (1988) Vertiges paroxystiques it\u00e9ratifs et Serc: \u00e9tude clinique control\u00e9e [Recurrent paroxysmal vertigo and Serc: a controlled clinical study]. Conc M\u00e9d 110:2539\u20132543","journal-title":"Conc M\u00e9d"},{"key":"2596_CR52","unstructured":"Cellier D (1987) Double-blind, randomised, multicentre trial comparing 8\u00a0mg Serc with placebo in patients suffering from repetitive paroxysmal vertigo with and without cochlear symptoms typical of M\u00e9ni\u00e8re\u2019s disease. Duphar report H 108 022 85 F\/M"},{"key":"2596_CR53","unstructured":"Conraux C, Cellier D (1988) Les sensations vertigineuses chroniques: essai comparatif Serc 8\u00a0mg versus placebo, double aveugle randomise, multicentrique chez des patients souffrant de sensations vertigineuse chroniques. [Chronic vertiginous sensations: a comparative double-blind randomized multicenter study of serc 8\u00a0mg versus placebo in patients suffering from chronic vertiginous sensations]. Impact M\u00e9dicin 260:63\u201365"},{"key":"2596_CR54","unstructured":"Cellier D (1987) Multicentre, randomized, double-blind, placebo-controlled trial of Serc 8\u00a0mg in patients suffering from chronic vertigo. Duphar report H 108 023 85 F\/M"},{"key":"2596_CR55","first-page":"122","volume":"14","author":"WJ Oosterveld","year":"1989","unstructured":"Oosterveld WJ, Blijleven W, Van Elferen LWM (1989) Betahistine versus placebo in paroxysmal vertigo: a double-blind trial. J Drug Ther Res 14:122\u2013126","journal-title":"J Drug Ther Res"},{"key":"2596_CR56","unstructured":"Van Elferen L (1987) Multi-centre randomised double-blind cross-over study using betahistine (Betaserc\u00ae) to treat forms of vertigo suitable for drug therapy. Duphar report H 108.904"},{"key":"2596_CR57","unstructured":"Maisonneuve H (1989) Double-blind, randomised, multicentre study to compare Serc 8\u00a0mg with placebo. Duphar report H 108 027 86 F\/M"},{"key":"2596_CR58","unstructured":"Salden JAHA (1990) A double-blind placebo-controlled study with betahistine (Betaserc) in forms of vertigo eligible for drug treatment. Duphar report H108.906 NL"},{"key":"2596_CR59","unstructured":"KirkPatrick CT, Saunders HF (1997) Double-blind, multi-centre, randomised, comparative study of Serc\u00ae 24\u00a0mg versus placebo, in two groups of patients with recurrent vertigo. Solvay Pharmaceuticals report H.108.035.92\/F"},{"key":"2596_CR60","unstructured":"Van Elferen L, Essers HJ (1997) Analyses of patient suffering from M\u00e9ni\u00e8re\u2019s disease; addendum to clinical report <double-blind, multi-centre, randomised, comparative study of Serc\u00ae 24\u00a0mg versus placebo, in two groups of patients with recurrent vertigo.> Solvay Pharmaceuticals report H.108.035.92\/F.02"},{"key":"2596_CR61","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s00405-002-0524-4","volume":"260","author":"E Mira","year":"2003","unstructured":"Mira E, Guidetti G, Ghilardi PL et al (2003) Betahistine dihydrochloride in the treatment of peripheral vestibular vertigo. Eur Arch Otorhinolaryngol 260:73\u201377","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"2596_CR62","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.2165\/00002018-200629110-00004","volume":"29","author":"S Jeck-Thole","year":"2006","unstructured":"Jeck-Thole S, Wagner W (2006) Betahistine: a retrospective synopsis of safety data. Drug Saf 29:1049\u20131059","journal-title":"Drug Saf"}],"container-title":["European Archives of Oto-Rhino-Laryngology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00405-013-2596-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00405-013-2596-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00405-013-2596-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,28]],"date-time":"2020-07-28T17:17:05Z","timestamp":1595956625000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00405-013-2596-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6,19]]},"references-count":62,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["2596"],"URL":"https:\/\/doi.org\/10.1007\/s00405-013-2596-8","relation":{},"ISSN":["0937-4477","1434-4726"],"issn-type":[{"value":"0937-4477","type":"print"},{"value":"1434-4726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,6,19]]}}}